GSK3B and neoplasm: Recent in vitro and in vivo studies in hepatocellular carcinoma models have demonstrated that the slow-releasing H2S donor GYY4137 significantly inhibits the phosphorylation of GSK-3β and β-catenin, thereby downregulating the AKT/GSK-3β/β-catenin pathway and promoting apoptosis in tumor cells [48].